期刊文献+

解读ESMO《高级别胶质瘤的诊断、治疗与随访指南》 被引量:4

下载PDF
导出
摘要 高级别胶质瘤主要指胶质母细胞瘤、间变性星形细胞瘤、间变性少突胶质细胞瘤和间变性少突星形细胞瘤,具有高复发率、致残率和致死率的特点。本文结合最新文献,对欧洲肿瘤内科学会制定的高级别胶质瘤指南中所涉及的流行病学、病理分型、分子标志、预后因素、治疗策略和缓解评估等细则进行详细介绍和解读。
出处 《国际神经病学神经外科学杂志》 2012年第6期566-569,共4页 Journal of International Neurology and Neurosurgery
基金 国家自然科学基金青年项目(项目编号:81001009)
  • 相关文献

参考文献22

  • 1Louis D,Ohgaki H,Wiestler O. WHO classification of tumours of the central nervous system[M].Lyon:International agency for research on cancer,2007.
  • 2Wen PY,Kesari S. Malignant gliomas in adults[J].New England Journal of Medicine,2008,(05):492-507.doi:10.1056/NEJMra0708126.
  • 3Stupp R,Tonn JC,Brada M. High-grade malignant glioma:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J].Annals of Oncology,2010,(Suppl 5):v190-v193.
  • 4Verhaak RG,Hoadley KA,Purdom E. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoms characterized by abnormalities in PDGFRA,IDH 1,EGFR,and NF1[J].Cancer Cell,2010,(01):98-110.doi:10.1016/j.ccr.2009.12.020.
  • 5Hofer S,Lassman AB. Molecular markers in gliomas:impact for the clinician[J].Target Oncol,2010,(03):201-210.
  • 6Weller M,Stupp R,Reifenberger G. MGMT promoter methylation in malignant gliomas:ready for personalized medicine[J].Nat Rev Neurol,2010,(01):39-51.
  • 7Glantz MJ,Cole BF,Forsyth PA. Practice parameter:anticonvulsant prophylaxis in patients with newly diagnosed brain tumors:report of the Quality Standards Subcommittee of the American Academy of Neurology[J].Neurology,2000,(10):1886-1893.
  • 8Lacroix M,Abi-Said D,Foumey DR. A multivariate analysis of 416 patients with glioblastoma multiforme:prognosis,extent of resection,and survival[J].Journal of Neurosurgery,2001,(02):190-198.doi:10.3171/jns.2001.95.2.0190.
  • 9Westphal M,Ram Z,Riddle V. Gliadel wafer in initial surgery for malignant glioma:longterm follow-up of a multicenter controlled trial[J].Acts Neurochir (Wien),2006,(03):269-275.
  • 10Molitemo JA,Patel TR,Piepmerier JM. Neurosurgical Approach[J].Cancer,2012,(01):20-25.

二级参考文献29

  • 1Lynn S Ashby(著),Timothy C Ryken(著),刘暌(译),只达石(校).恶性胶质瘤的治疗:综合方案的进展[J].中国现代神经疾病杂志,2006,6(6):453-458. 被引量:8
  • 2毛更生,只达石.干细胞对脑胶质瘤定向迁移的研究进展[J].国际神经病学神经外科学杂志,2007,34(1):44-48. 被引量:2
  • 3Pisati F Belicchi M Acerbi F Marchesi C Giussani C Gavina M Javerzat S Hagedorn M Carrabba G Lucini V Gaini SM Bresolin N Bello L Bikfalvi A Torrente Y.Effect of human skin-derived stem cells on vessel architecture, tumor growth, and tumor invasion in brain tumor animal models[J].中国神经肿瘤杂志,2007,5(2):146-146. 被引量:10
  • 4Weave JL, Szabo GJ, Pine PS, et al. The effect of ion channel blockers, immunosuppressive agents and other drugs on the activity of the multidrug transporter, lnt J Cancer, 1993, 54(3) : 456-461.
  • 5Tanaka S, Kamitani HT, Amin MR, et al. Preliminary individual adjuvant therapy for gliomas based on the results of molecular biological analyses for drug-resistance genes. J Neurooncol, 2000, 46(2) :157-171
  • 6Demeule M, Shedid D, Beaulieu E. Expression of multidrugresistance P glycoprotein (p-gp) in human brain tumors, lnt J Cancer, 2001, 93(1): 62-66.
  • 7Calatozzolo C, Gelati M, Ciusani E, et al. Expression of drug resistance proteins Pgp, MRP1 , MRP3, MRP5 and GST-pi in human glioma. J Neurooneol, 2005 , 74 ( 2 ) : 113-121.
  • 8Usarek E, Kazmierezak B, Bojanowski K, et al. Expression of glutathione S-transferase isoenzymes in human gliomas. Pol Merkur Lekarski, 2005, 18(108) : 676-679.
  • 9Hao Y J, Natsume A, Mizuno M, et al. Correlation between DNA topoisomerase II alpha expression and sensitivity to etoposide in human glioma cell lines. Gan To Kagaku Ryoho, 2000, 27(9) : 1403-1409.
  • 10Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med, 2005, 352(10): 997-1003.

共引文献13

同被引文献46

  • 1张皓,沈天真,陈星荣,缪竞陶,解学乾.MR灌注成像在鉴别单发脑转移瘤与高级别胶质瘤中的价值[J].中华放射学杂志,2006,40(4):393-396. 被引量:25
  • 2刘英姿,张学新,张磊,邢鹏辉.单用替莫唑胺与替尼泊甙联合洛莫司汀治疗恶性胶质瘤的比较[J].临床荟萃,2007,22(16):1154-1156. 被引量:4
  • 3Central brain tumor registry of the United States. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004 - 2007. Hinsdale, IL: 2011. http://www, cbtrus, org/2011- NPCR-SEER/WEB -0407 -Report-3 -3 -2011. pdf. Access- ed 27 May 2013.
  • 4Rolle CE, Sengupta S, Lesniak MS. Challenges in clinical design of immunotherapy trials for malignant glioma. Neuro- surgery clinics of North America, 2010, 21 ( 1 ) : 201- 214.
  • 5Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5. 1.0 [ updated March 2011]. The Cochrane Collaboration, 2011.
  • 6Availa- ble from www. cochrane-handbook, org. ReviewManager ( RevMan ) ( Computer program ) . Version 5. 2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
  • 7Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high- grade glioma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2010,28 ( 30 ) : 4601-4608.
  • 8Osoba D, Brada M, Yung WK, et al. Health-related quality of life in patients treated with temozolomide versus procarba- zine for recurrent glioblastoma muhiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oneology,2000,18 (7) : 1481 -1491.
  • 9Niewald M, Berdel C, Fleckenstein J, et al. Toxicity after radiochemotherapy for glioblastoma using temozolomide a retrospective evaluation. Radiat Oncol, 2011, 21 (6) : 141- 147.
  • 10Terri S, Armstrong, Yumei Cao, et al. Risk analysis of se- vere myelotoxicity with temozolomide: The effects of clinical and genetic factors. Neuro Onco|, 2009, 11 (6) : 825- 832.

引证文献4

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部